Previous studies had demonstrated that EGFR and ERBB2 amplification was associated with sensitivity to lapatinib, which has been licensed for the treatment of HER2+ breast cancer clinically (Petrelli et al., 2017; Zhao et al., 2017). Here, EGFR is linked to breast cancer.